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Background: Epidemiological studies suggest that serum calcium levels correlate with cardiovascular events. An 
ankle-brachial index (ABI) between 0.9 and 1.00 is a surrogate estimation of preclinical peripheral arterial disease 
(PAD). Prior studies have shown that an ABI of 0.9–1.0 is also associated with endothelial dysfunction. Therefore, 
we sought to investigate the relationship between serum calcium levels and preclinical PAD in apparently healthy 
Korean individuals.
Methods: We evaluated the association between serum calcium levels and preclinical PAD in 596 participants (334 
males, 262 females) in a health examination program. Preclinical PAD was defined by an ABI of 0.9–1.0. Multiple 
logistic regression analysis was used to determine whether the serum calcium level was an independent determi-
nant of preclinical PAD.
Results: The overall prevalence of preclinical PAD was 14.3%. The mean age was 44.0±12.5 years in the non-PAD 
group and 48.3±11.4 years in the preclinical PAD group (P=0.001). After adjusting for age, gender, systolic blood 
pressure, fasting plasma glucose, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, g-glutamyl-
transferase, uric acid, hypertension medication, diabetes medication, and hyperlipidemia medication, the odds ra-
tio (95% confidence intervals) for preclinical PAD was 2.28 (1.02–5.11) with a 1-mg/dL increase in the serum calci-
um.
Conclusion: These findings suggest that increased serum calcium is independently and positively associated with 
preclinical PAD regardless of the presence of classic cardiovascular risk factors.
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INTRODUCTION
Calcium is a pervasive divalent cation that is involved in blood coagu-
lation, skeletal mineralization, muscle withdrawal, and nerve sensitiv-
ity. It is finely managed by the balance of calcitonin and parathyroid 
hormone (PTH).1,2) Epidemiological data over time suggest that serum 
calcium levels are associated with cardiovascular events.1) Calcium 
supplementation is thought to be beneficial for bone health in chil-
dren, young adults, the elderly, and menopausal females. However, 
there is also a concern regarding the possible relationship between se-
rum calcium and incident cardiovascular illness.1) Elevated serum cal-
cium may have an early effect on cardiovascular morbidity through its 
effects on arterial stiffness.3) Several mechanisms may explain calci-
um’s effects on cardiovascular morbidity. An increased serum calcium 
level affects pyrophosphate, which is an important inhibitor of tissue 
calcification, by binding to the calcium-sensing receptor and altering 
endothelial function. In addition, elevated serum calcium levels can 
influence blood coagulation, thereby increasing the rates of cardiovas-
cular events and mortality.3)
 The ankle-brachial index (ABI) is a simple, noninvasive clinical test 
that is not only useful in the diagnosis of peripheral arterial disease 
(PAD) but also in yielding important prognostic information about fu-
ture cardiovascular events.4-9) Measuring the ABI involves recording 
the systolic pressures in the brachial artery at each elbow, in the poste-
rior tibial artery, and in the dorsalis pedis arteries at each ankle.4,9,10) 
The ratio of the ankle systolic pressure to the higher brachial pressure 
can then be ascertained.4,10-12) The ABI is calculated for each leg sepa-
rately, and the lower of the two values is considered the result.9,12) PAD 
is diagnosed by an ABI of ≤0.9 and graded as mild to moderate if the 
ABI is between 0.4 and 0.9 and severe if <0.40.5-7,10) An ABI value >1.4 is 
also considered abnormal and suggestive of non-compressible ves-
sels.5-7,10)
 Previous studies have found ABIs of 0.9–1.00 to be associated with 
endothelial dysfunction.5) The association between serum calcium 
level and borderline ABI (as a surrogate marker of preclinical PAD) is 
poorly understood. Therefore, we sought to investigate the relation-
ship between serum calcium level and preclinical PAD, as defined by 
an ABI of 0.9–1.0, in apparently healthy Korean individuals.
METHODS
1. Study Population
We reviewed the medical records of 728 individuals (416 men, 312 
women) who voluntarily underwent a medical examination at a health 
promotion center in the tertiary university hospital between March 
2006 and May 2007. Individuals were excluded if they met any of the 
following criteria (n=45): missing covariate information, ABI <0.9 or 
>1.4, or C-reactive protein >3.0. Ultimately, 596 participants (334 
males, 262 females) were included in the final analysis. This study was 
approved by the Institutional Review Board of the medical institutions 
(IRB approval no., 3-2017-0201). Informed consent was obtained from 
each participant.
2. Data Collection
The medical staff performed every examination according to the same 
procedures. Participants were asked about their lifestyle (including 
cigarette smoking, alcohol consumption), physical activity (more or 
less than two times per week), and whether or not they were currently 
being treated for any disease. If the patients were currently being treat-
ed for a specific condition, they were asked for the date of diagnosis 
and a list of their current medications. Trained staff reviewed the com-
pleted questionnaires and entered the responses into a database. Par-
ticipants were also categorized into non-drinkers, abstainers (<140 g/
wk of alcohol), or current drinkers (≥140 g/wk of alcohol). Body weight 
and height were measured in light indoor clothing (without shoes) to 
the nearest 0.1 kg and 0.1 cm, respectively. Body mass index (BMI) was 
calculated as the weight divided by the height squared (kg/m2).
 Blood samples were drawn from an antecubital vein after a 12-hour 
overnight fast. Fasting plasma glucose, high-density lipoprotein (HDL) 
cholesterol, triglycerides, C-reactive protein, g-glutamyltransferase 
(GGT), and uric acid were measured using a Hitachi 7600-110 Chem-
istry system Autoanalyzer (Hitachi, Tokyo, Japan). Blood pressure was 
measured using an automated device (TM-2665; A&D Co. Ltd., Tokyo, 
Japan) with the participant in a seated position after five minutes of 
rest. Diabetes was defined as a self-reported history or by a fasting 
plasma glucose level ≥126 mg/dL. Hypertension was defined as a self-
reported history, systolic blood pressure ≥140 mm Hg, or diastolic 
blood pressure ≥90 mm Hg.
3. Ankle-Brachial Index Acquisition
An automated oscillometric device (Form PWV/ABI; BP-203PRE II In-
strument Omron Colin Co., Komaki, Japan) was used to calculate ABI 
by simultaneously measuring the systolic pressures at bilateral brachi-
al and ankle arteries. With the subject in the supine position, systolic 
blood pressures were measured at the brachial arteries and in both the 
dorsalis pedis and posterior tibial arteries of the lower extremities.4,10,12) 
The ABI was calculated separately for each leg by dividing the higher 
of the two ankle systolic pressures by the higher of the two brachial 
systolic pressures.4,10) According to the definition from the American 
Heart Association scientific statement, the ABI is the ratio of the systol-
ic blood pressure measured at the ankle to that at the brachial ar-
tery.10,12)
4. Statistical Analyses
The demographic and biochemical characteristics of the study popu-
lation according to preclinical PAD were compared using independent 
two-sample t-tests for continuous variables and the chi-square test for 
categorical variables. A multiple logistic regression analysis was per-
formed to determine whether the serum calcium level is an indepen-
dent determinant of preclinical PAD. All analyses were conducted us-
ing the SAS statistical software ver. 9.1 (SAS Institute Inc., Cary, NC, 
USA). All statistical tests were two-sided. Statistical significance was 
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determined by a P-value <0.05.
RESULTS
Table 1 shows the general characteristics of the study population 
(n=596). The overall prevalence of preclinical PAD was 14.3%. The 
mean age was 44.0±12.5 years in the non-PAD group and 48.3±11.4 
years in the preclinical PAD group (P=0.001). The mean BMI (kg/m2) 
was 23.8±2.9 in the control group and 23.5±2.9 in the preclinical PAD 
group (P=0.404). Fasting plasma glucose and C-reactive protein levels 
were higher in the preclinical PAD group than in the control group, al-
though these differences were not statistically significant.
 Figure 1 shows the unadjusted spline curve between serum calcium 
levels and preclinical PAD. The probability of preclinical PAD gradually 
increased according to serum calcium. Figure 2 shows the spline curve 
between serum calcium levels and preclinical peripheral arterial dis-
ease after adjusting for the same variables on Table 2, and the results 
showed that the logarithm of odds ratio for ABI lower than 1.0 tends to 
be increasing according to serum calcium level.
 Table 2 shows the risk of preclinical PAD according to changes in the 
serum calcium levels. After adjusting for age, gender, systolic blood 
pressure, fasting plasma glucose, HDL cholesterol, triglycerides, C-re-
active protein, GGT, uric acid, hypertension medication, diabetes 
medication, and hyperlipidemia medication the odds ratio (95% CIs) 
of preclinical PAD was 2.28 (1.02–5.11) with a 1-mg/dL increase in the 
calcium level (P=0.046). In addition, the odds ratio (95% confidence 
intervals) for a history of hyperlipidemia medication for preclinical 
PAD was 3.67 (1.33–10.14; P=0.012).
DISCUSSION
In this population based, cross-sectional study, there was a positive as-
sociation between higher serum calcium levels and preclinical PAD 
(independent of classic cardiovascular risk factors). Preclinical PAD 
Table 1. Characteristics of the study population
Characteristic Total (n=596) Control (n=511)
Preclinical peripheral arterial 
disease (n=85)
P-value
Age (y) 47.7±11.6 44.0±12.5 48.3±11.4 0.001
Body mass index (kg/m2) 23.7±2.9 23.8±2.9 23.5±2.9 0.404
Current smoker 22.2 23.7 12.9 0.027
Alcohol consumption 71.5 71.6 70.6 0.845
Regular exercise 59.1 57.1 70.6 0.020
Systolic blood pressure (mm Hg) 119.5±15.3 120.0±15.7 116.8±12.6 0.077
Fasting plasma glucose (mg/dL) 96.1±18.4 96.0±15.4 96.7±15.4 0.840
Triglyceride (mg/dL) 112.7±94.0 114.1±97.1 104.0±72.2 0.966
High-density lipoprotein cholesterol (mg/dL) 48.1±12.6 48.1±12.5 48.2±13.2 0.965
C-reactive protein (mg/L) 0.6±0.6 0.6±0.6 0.7±0.7 0.347
g-Glutamyltransferase (U/L) 24.3±15.9 24.8±16.2 21.1±13.7 0.045
Uric acid (mg/dL) 5.2±1.4 5.2±1.4 4.9±1.4 0.070
Hypertension 12.3 12.5 10.6 0.614
Diabetes 4.2 4.5 2.4 0.360
Values are presented as mean±standard deviation or %.
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Figure 1. Unadjusted spline curve between serum calcium levels and preclinical 
peripheral arterial disease.
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Figure 2. Adjusted spline curve between serum calcium levels and preclinical 
peripheral arterial disease.
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was defined as an ABI of 0.9–1.0. An ABI in this range has also been 
correlated to endothelial dysfunction, which is the initial step in the 
pathogenesis of atherosclerosis.5) Although the endothelium is only a 
single layer of simple cells, it performs numerous critical homeostatic 
functions13) and is the target of vascular inflammation and thrombosis. 
It is also the main site of atherosclerosis and its clinical ramifications, 
including myocardial infarction and stroke.13) In the presence of car-
diovascular risk factors, including hypercholesterolemia, hyperten-
sion, diabetes, and smoking, the endothelium has decreased nitro ox-
ide accessibility. Ultimately, this change damages the endothelium 
and its ability to vasodilate.5,13) Such endothelial dysfunction increases 
the risk of major cardiovascular morbidity.13)
 To prevent cardiovascular events, it is clinically imperative that the 
treatment of atherosclerosis be properly researched before progres-
sion to advanced atherosclerosis with gravely injured vessels.10,14) Cer-
tain mechanisms may explain the significant relationship between se-
rum calcium levels and cardiovascular diseases.3) Accumulating evi-
dence demonstrates that higher serum calcium levels are associated 
with increased risk of cardiovascular events. For example, there is in-
creased carotid artery plaque thickness and abdominal aortic calcifi-
cation in individuals with elevated calcium levels, suggesting that cal-
cium directly affects the vessel walls.3) Arterial stiffness is also known 
to be associated with cardiovascular disease.15) Another possible 
mechanism is through the binding of calcium with pyrophosphate, 
which is an important inhibitor of tissue calcification. In the context of 
excess serum calcium, there is reduced pyrophosphate, and subse-
quently there may be more tissue calcification.1,2,16)
 PTH levels are also implicated in the relationship between serum 
calcium levels and cardiovascular disease. PTH inhibits arteriosclerot-
ic Wnt/b-catenin signaling in vascular smooth muscle cells. However, 
elevated serum calcium levels reduce the PTH level and thereby influ-
ence vascular wall function.3,17) 
 Prior studies have demonstrated a noteworthy and straightforward 
relationship between serum calcium level and lipids. In addition, es-
trogens are thought to neutralize the ominous impact of serum calci-
um on lipid metabolism. Likewise, serum calcium supplementation 
may contribute to increased serum cholesterol by diminishing hepatic 
catabolism in cases of estrogen deficiency. Ordinarily, estrogen acti-
vates the low-density lipoprotein cholesterol receptor and therefore 
enhances both cholesterol catabolism and lipid synthesis. In contrast, 
calcium decreases cholesterol catabolism and stimulates lipid synthe-
sis. Hence, a combination of calcium supplementation and an ab-
sence of estrogens may impair the lipid profile and increase cardiovas-
cular risk.2)
 Our study has several limitations. First, the research population may 
not adequately represent the general Korean population given that the 
participants were otherwise healthy volunteers. We found that age is 
not related to the diagnosis of preclinical PAD. Moreover, since we 
conducted our research on healthy adults, unknown genetic factors 
could have influenced our results. Second, this study is a cross-sec-
tional study, suggesting that caution should be used in causal and 
temporal interpretations. Additional studies in extensive, prospective 
investigations over an extended period of time are warranted. Third, 
PTH and vitamin D were not measured at the beginning of this study. 
Additional prospective studies in a large patient population are need-
ed to substantiate these findings. Lastly, in the present study, as the se-
rum calcium increases the probability of ABI lower than 1.0 tended to 
be stabilized in the adjusted spline curve. Relatively small numbers of 
participants with serum calcium level >9.5 mg/dL were included in 
the study population.
 In conclusion, our findings demonstrate that increased serum calci-
um levels are independently and positively associated with preclinical 
PAD irrespective of classical cardiovascular risk factors in apparently 
healthy Korean adults.
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